Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979057 | PMC |
| http://dx.doi.org/10.1177/24741264211002801 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Ann Hematol
January 2025
Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
Calreticulin (CALR) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with JAK2-inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the CALR mutant clone have entered clinical investigation.
View Article and Find Full Text PDFHE Breathing: a new ventilation mode in airway surgery.
J Thorac Dis
December 2024
Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Editorial Commentary.
J Hum Reprod Sci
December 2024
Editor in Chief, Journal of Human Reproductive Sciences, Christian Medical College, Vellore, Tamil Nadu, India.
Vitiligo Exchange: An Expert Panel Discussion of Two Clinical Cases.
J Clin Aesthet Dermatol
December 2024
Dr. Grimes is the Founder and Director at the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, California; Clinical Professor of Dermatology at the University of California, Los Angeles. Current President of the Global Vitiligo Foundation.
This article is based on a roundtable discussion in which three panelists review clinically relevant insights about vitiligo and discuss two cases that illustrate the multiple challenges faced by both patients and clinicians in managing this complex disease. The first is a 32-year-old White female patient with Fitzpatrick Skin Type III/IV with extensive depigmentation in the trunk area. The patient achieved 90-percent repigmentation with a combination therapy approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!